1. Introduction

   • P. S. Sørensen
   • C. C. Ford
   • O. Fernández y Fernández

   OriginalPaper Pages: vi1 - vi2

2. Disease evolution in multiple sclerosis

   • George C. Ebers

   OriginalPaper Pages: vi3 - vi8

3. The importance of long-term data in multiple sclerosis

   • Xavier Montalban

   OriginalPaper Pages: vi9 - vi15

4. Neutralising antibodies to interferon-β–measurement, clinical relevance, and management

   • Per Soelberg Sørensen

   OriginalPaper Pages: vi16 - vi22

5. Assessing long-term effects of disease-modifying drugs

   • Bernd C. Kieseier

   OriginalPaper Pages: vi23 - vi30

6. Measuring disability progression in multiple sclerosis

   • Anat Achiron

   OriginalPaper Pages: vi31 - vi36

7. Long-term experience with current disease-modifying drugs in multiple sclerosis

   • Corey C. Ford

   OriginalPaper Pages: vi37 - vi44

8. Rationale and experience with combination therapies in multiple sclerosis

   • Mike Boggild

   OriginalPaper Pages: vi45 - vi51